Alex Drebin

Alex Drebin is an Executive Director and equity research analyst at Morgan Stanley, specializing in the coverage of major North American specialty pharmaceuticals and biotechnology companies. He has provided in-depth analysis on key firms such as Amgen, Biogen, Gilead Sciences, and Vertex Pharmaceuticals, contributing research that has consistently aided investors in making informed decisions—a track record reflected in strong published ratings and recognized by industry platforms. Drebin began his research career at Morgan Stanley, steadily advancing through the analyst ranks since joining the firm in the early 2010s, with prior experience at Duff & Phelps and Citi. He holds FINRA Series 7, 63, 86, and 87 licenses, underlining his credentials as a registered securities professional.